ClinicalTrials.gg
RecruitingNCT06684119Updated Feb 7, 2025

Pediatric Positive End Expiratory Pressure (PEEP) Titration Using Electrical Impedence Tomography (EIT)

An interventional study of Electrical Impedance Tomography positive end-expiratory pressure titration in Pediatric Acute Respiratory Distress Syndrome, sponsored by Children's Hospital Los Angeles. Recruiting at 1 site in United States. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Children's Hospital Los Angeles · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies in Dyspnea with a site in United States — 31 open to participants now, 37 under way, 1 of them phase 3. Dyspnea · United States.

Planned enrollment
61st of 151
60 · median 36
Started
2024
with 12 others
No phase
84 of 214
18 open now
Primary completion
2027-01
later than 13 of 36 live
Registered
196th of 214
by date

Among the 214 studies in Dyspnea with a site in United States, this one is the 61st largest by planned enrollment of the 151 interventional ones that give a count, is one of 13 that started in 2024, is one of 84 with no phase, reaches primary completion later than 13 of the 36 other live ones, and was the 196th registered.

Dyspnea

895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.

Browse Dyspnea studies →

Open to participants now

31 of the 214 studies in Dyspnea with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Dyspnea with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to perform a PEEP titration protocol and use EIT to identify the optimal PEEP at which lung overdistention and collapse are most effectively balanced. The primary and secondary aims of the study are as follows:

Identify the difference between the optimal PEEP recommended by EIT metrics and the current guideline recommended approach to identifying optimal PEEP in PARDS. There will be a statistically significant difference in the recommended optimal PEEP identified using the EIT PEEP titration tool and that of the PEEP/FiO2 grid recommendations.

Determine the difference in physiologic metrics between EIT optimal PEEP and the PEEP/FiO2 recommended PEEP.

Participants will undergoing EIT monitoring while being subjected to PEEP titration protocol.

03

Conditions studied

  • Pediatric Acute Respiratory Distress Syndrome

Browse trials for

Keywords

  • positive end-expiratory pressure
  • Electrical Impedance Tomography
  • respiratory distress
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any person who is less than 18 years of age
  • is on invasive mechanical ventilation
  • is not spontaneously breathing
  • meets PARDS criteria

Exclusion criteria

Exclusion Criteria:

  • to the use of EIT
  • Hemodynamic instability
  • Contraindications to hypercapnia
  • patients with uncuffed endotracheal or tracheostomy tubes
  • diagnosis of pneumothorax or bronchopleural fistula
  • non-conventional ventilation
  • any patient on extra-corporeal membrane oxygenation (ECMO) support
  • less than 1 week post-operatively from cardiac surgery
  • the following cardiac diagnoses: Glenn or Fontan physiology, significant right to left shunt
  • Corrected Gestational Age \< 37 weeks
  • pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Electrical Impedance Tomography positive end-expiratory pressure

    Patients will be monitored using Electrical Impedance Tomography and the positive end-expiratory pressure titration tool as their positive end-expiratory pressure is adjusted according to a step wise positive end-expiratory pressure titration protocol.

    Device: Electrical Impedance Tomography positive end-expiratory pressure titration

Interventions

  • DeviceElectrical Impedance Tomography positive end-expiratory pressure titration

    A PEEP titration will occur for the patient with the PEEP increased by 2 cm H2O every 2 minutes until a maximum PEEP of 20 or three steps (+ 6 cm H2O) above the set clinical PEEP. The PEEP will then be decreased by 2 cmH2O every 2 minutes until a minimum PEEP of 6 cmH2O or three steps (- 6 cm H2O) below their clinical PEEP.

06

What researchers measure

Primary outcomes

  1. The absolute difference between the electrical impedence tomography (EIT) recommended PEEP and the PEEP recommended by the PEEP/fraction of inspired oxygen (FiO2) grid.

    Collected using electrical impedence tomography (EIT). The EIT device provides the percentages of alveolar overdistention and collapse at each PEEP level. The best PEEP by EIT is defined as the PEEP level above the intersection of curves representing relative alveolar overdistention and collapse.

    Time frame: Day 1

Secondary outcomes

  1. Lung recruitability, as measured by electrical impedence tomography, and its association with difference in optimal PEEP recommended by electrical impedence tomography versus the PEEP/FiO2 grid

    Recruitability will be defined as the absolute reduction in the percentage of collapse when comparing the highest and lowest PEEP achieved, as measured by electrical impedence tomography.

    Time frame: Day 1

  2. Difference in systolic impendence, as a surrogate for cardiac output, using electrical impedence tomography at various PEEP levels

    Using the electrical impedence tomography pulsatility filter/tool, a difference in systolic impendence, attributed to the cardiac cycle, can be calculated. This will be used as a surrogate for stroke volume and will be compared across PEEP levels.

    Time frame: Day 1

  3. Change in static compliance across different PEEP levels during a PEEP titration

    Static compliance is defined as the change in volume divided by the change in pressure during an inspiratory hold (when airflow is zero). It reflects the elastic properties of the lung and chest wall.

    Time frame: Day 1

  4. Change in driving pressure across different PEEP levels during a PEEP titration

    Driving pressure is the difference between the plateau pressure (the pressure measured during an inspiratory hold, when airflow is zero) and the positive end-expiratory pressure (PEEP). It represents the pressure that actually distends the alveoli during mechanical ventilation.

    Time frame: Day 1

  5. Change in plateau pressure across different PEEP levels during a PEEP titration

    Plateau pressure is the pressure measured during an inspiratory hold maneuver, which occurs when the ventilator temporarily halts airflow at the end of the inspiratory phase. This allows the pressure in the alveoli to stabilize, providing a true reflection of the pressure needed to distend the lungs, without the effects of airflow resistance.

    Time frame: Day 1

  6. Change in dead space, as measured by volumetric capnography, across different PEEP levels during a PEEP titration

    For patients who consent to the optional placement of a volumetric capnography device, dead space will be continuously measured using volumetric capnography by measuring the volume of carbon dioxide (CO2) exhaled with each breath (VeCO2) and calculating the CO2 ventilatory equivalent (minute ventilation/VCO2). Airway dead space can be obtained with each breath.

    Time frame: Day 1

  7. Change in transplural pressure, as measured by esophageal manometry, across different PEEP levels during a PEEP titration

    For patients who consent to the optional component of having an esophageal balloon catheter placed, esophageal manometry will be used to measure transplural pressure. The difference between the pressure in the alveoli (intrapulmonary pressure) and the pressure in the pleural space (intrapleural pressure). It reflects the pressure required to expand the lungs and is crucial for understanding lung mechanics. This will be obtained using esophageal manometry with inspiratory and expiratory holds at each PEEP titration level.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 24 months is above that.

Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 12, 2024
StartActual
Dec 10, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06684119
Responsible party
Anoopindar Bhalla (Medical Staff/USC Faculty, Children's Hospital Los Angeles) — Principal investigator
First posted
Nov 12, 2024
Start date
Dec 10, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Feb 7, 2025

Study contacts

Hayden Leeds, MD
Contact
hleeds@chla.usc.edu
3233617939
Anoopindar Bhalla, MD
Contact
abhalla@chla.usc.edu
323-361-7939
Anoopindar Bhalla, MD
study director · Children's Hospital Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion